Benjamin Treichl

Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial.

A. Mayr, P. Innerhofer, D. Fries, 2017, The Lancet. Haematology.

Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC)

W. Voelckel, M. Kaufmann, M. Maegele, 2020, European journal of anaesthesiology.

First-Line Administration of Fibrinogen Concentrate in the Bleeding Trauma Patient: Searching for Effective Dosages and Optimal Post-Treatment Levels Limiting Massive Transfusion—Further Results of the RETIC Study

P. Innerhofer, D. Fries, T. Hell, 2021, Journal of clinical medicine.

Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients.

W. Schobersberger, S. Rajsic, D. Fries, 2022, Seminars in thrombosis and hemostasis.

Fibrinogen supplementation ex vivo increasesclot firmness comparable to platelet transfusion in thrombocytopenia.

M. Hermann, D. Fries, O. H. Larsen, 2016, British journal of anaesthesia.

Fibrinogen levels in trauma patients during the first seven days after fibrinogen concentrate therapy: a retrospective study

W. Voelckel, M. Maegele, H. Schöchl, 2016, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.

Efficacy of Pre-Hospital Administration of Fibrinogen Concentrate (Clottafact®) in Trauma Patients Presumed to Bleed (FIinTIC): Results from a Multicentre Double-Blind, Placebo-Controlled, Randomised, Pilot Trial

W. Voelckel, M. Kaufmann, M. Maegele, 2019, SSRN Electronic Journal.

A Prospective Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients with Heparin Resistance †

D. Fries, M. Bachler, B. Wallner, 2020, Journal of clinical medicine.